PUS1 is a novel biomarker for predicting poor outcomes and triple-negative status in breast cancer.
Ontology highlight
ABSTRACT: Breast cancer patients' outcomes have improved dramatically in recent years, but relapses and poor prognosis remain common due to its aggressiveness and heterogeneity. The development of reliable biomarkers is still needed for predicting prognosis and treatment effectiveness. Recently, a growing body of research suggests that pseudouridine synthases contribute to the development of many cancers, but their contribution to breast cancer remains largely unknown. Using an integrative analysis, we selected pseudouridine synthase1(PUS1) as the candidate biomarker. A tissue microarray of 131 breast cancer patients was then utilized to determine the clinical significance and prognostic value of PUS1. RNA sequencing analysis was conducted to identify downstream genes that differ between control and
SUBMITTER: Fang Z
PROVIDER: S-EPMC9705787 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature
ACCESS DATA